Related Experiment Video
Updated: Jun 5, 2026
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
Published on: April 3, 2016
Intradermal tacrolimus prevent scar hypertrophy in a rabbit ear model: a clinical, histological and spectroscopical
Heloise Gisquet1, Honghui Liu, W C P M Blondel
1Research Centre in Automatic Control (CRAN), Nancy-University, CNRS UMR, Cedex, France. helogisqu@hotmail.com
Background:
Keloids and hypertrophic scars (HSc) affect 4.5-16% of the population. Thus far, the different approaches of keloid treatment are not very efficient, with a 50% relapse rate and many ongoing researches are looking for simple, safe and more efficient therapeutic methods. Tacrolimus is an immunomodulator that could be useful in treating keloid.
Objectives:
The objective of this study is to evaluate the effectiveness of Tacrolimus in inhibiting HSc formation on rabbits' ears model and to check optical skin spectroscopy in tissue characterization.
Methods:
Our study was carried out on 20 New-Zealand female white rabbits. HSc were obtained by wounding rabbits' ear. These wounds were treated with intradermal injections of tacrolimus (0.2-0.5 mg/cm(2)) or a vehicule. The assessment of treatment efficacy was performed by clinical examinations, histological assay and skin spectrometry.
Results:
Tacrolimus did not induce general or local side-effects. The scar elevation index in treated subjects was half less than that of the untreated ones. Furthermore, dermal thickness and inflammatory cellular density were both significantly smaller for treated scars than for the control ones. In vivo optical skin spectroscopy can characterize hypertrophic and normal skin with high sensibility and specificity.
Conclusion:
Intradermal injection of tacrolimus at 0.5 mg/cm(2) is an efficient way to prevent HSc in our experiment model and its tolerance is correct. Optical spectroscopy could be a good non-invasive tool to evaluate HSc treatment. These promising results might be proposed for patients suffering from keloid.
Insights
Tacrolimus effectively reduced hypertrophic scar (HSc) formation in rabbits by half, with no adverse effects. This immunomodulator shows promise for keloid treatment and scar assessment using optical spectroscopy.
Area of Science:
- Dermatology
- Immunology
- Medical Technology
Background:
- Keloids and hypertrophic scars (HSc) affect a significant portion of the population, with current treatments having limited efficacy and high relapse rates.
- There is a continuous need for simple, safe, and more effective therapeutic strategies for keloid management.
- Tacrolimus, an immunomodulator, presents potential therapeutic benefits for keloid treatment.
Purpose of the Study:
- To evaluate the efficacy of Tacrolimus in preventing HSc formation using a rabbit ear model.
- To assess the utility of optical skin spectroscopy for characterizing HSc and normal skin tissue.
Main Methods:
- The study involved 20 New Zealand white rabbits where HSc were induced by wounding.
- Wounds were treated with intradermal injections of Tacrolimus (0.2-0.5 mg/cm²) or a vehicle control.
- Treatment efficacy was evaluated through clinical examinations, histological analysis, and in vivo optical skin spectroscopy.
Main Results:
- Tacrolimus treatment resulted in a 50% reduction in scar elevation index compared to controls.
- Histological analysis showed significantly reduced dermal thickness and inflammatory cell density in Tacrolimus-treated scars.
- In vivo optical skin spectroscopy demonstrated high sensitivity and specificity in differentiating HSc from normal skin.
Conclusions:
- Intradermal Tacrolimus at 0.5 mg/cm² effectively prevented HSc formation in the experimental model with good tolerance.
- Optical spectroscopy is a promising non-invasive tool for evaluating HSc treatment outcomes.
- These findings suggest Tacrolimus as a potential treatment option for patients with keloids.
